Semaglutide’s effectiveness, safety, and continued use for obesity in different sexes, body weights, and previous treatments

Semaglutide may lead to significant weight loss in individuals with obesity over 12 months.

• Weight loss in kilograms and percentage is evaluated at mean follow-up intervals of 3 months, 6 months, and 12 months.
• The percentage of participants achieving weight loss targets of 5%, 10%, and 15% is assessed.
• Safety and reasons for discontinuation are included in the evaluation.
• Sub-analyses are planned to explore anthropometric outcomes based on prior exposure to liraglutide, sex, and BMI categories.

Simplified